Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin’s disease

FH Blackhall¹, AD Atkinson³, MB Maaya¹, WDJ Ryder², G Horne⁴, DR Brison⁴, BA Lieberman⁴ and JA Radford*¹

*Correspondence: JA Radford; E-mail: john.radford@man.ac.uk

1Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK; 2Department of Medical Statistics, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK; 3Subfertility Laboratory, Central Manchester and Manchester Childrens University Hospitals NHS Trust, Hathersage Road, Manchester M13 0JH, UK; 4Department of Reproductive Medicine, Central Manchester and Manchester Childrens University Hospitals NHS Trust, Hathersage Road, Manchester M13 0JH, UK

Between 1978 and 1990, 122 men underwent semen analysis before starting sterilising chemotherapy for Hodgkin’s disease. Eighty-one (66%) had semen quality within the normal range, 25 were oligospermic (<20 x 10⁹ sperm per ml) and five were azoospermic (no sperm in the ejaculate). Semen from 115 men was cryopreserved and after a median follow-up time of 10.1 years, 33 men have utilised stored semen (actuarial rate 27%) and nine partners have become pregnant resulting in 11 live births and one termination for foetal malformation. Actuarial 10 year rates of destruction of semen before death or utilisation and death before utilisation are 19% and 13% respectively. This retrospective cohort study demonstrates that approximately one-quarter of men utilising cryopreserved semen after treatment for Hodgkin’s disease obtain a live birth. The high non-utilisation rate is intriguing and warrants further investigation.

British Journal of Cancer (2002) 87, 381 – 384. doi:10.1038/sj.bjc.6600483 www.bjcancer.com © 2002 Cancer Research UK

Keywords: semen cryopreservation; reproductive outcome; Hodgkin’s disease

Most patients with Hodgkin’s disease can expect prolonged survival due to the success of chemotherapy regimens which have evolved since the first introduction of MOPP (mustine, vincristine, procarbazine and prednisolone) in 1964 (De Vita et al, 1972). Unfortunately, infertility is a common late effect of treatment and particularly important since most patients are young adults at diagnosis (Whitehead et al, 1982). Semen cryopreservation is currently the only available technique to preserve reproductive potential in men undergoing potentially sterilising treatments and in the UK is offered routinely to patients who are under 55 years of age. However, little information exists as to the benefits of this policy. In this study, semen quality before and after chemotherapy, rates of utilisation of cryopreserved semen and reproductive outcome have been analysed in a cohort of 122 men who presented to a regional cancer centre with newly diagnosed Hodgkin’s disease between 1978 and 1990.

PATIENTS AND METHODS

Names of all male patients with newly diagnosed Hodgkin’s disease registered at the Christie Hospital were cross-matched with the names of patients referred for semen cryopreservation at St Mary’s Hospital, Manchester between January 1978 and December 1990. Permission to gather information from the files at St Mary’s Hospital, Manchester was obtained from the Human Fertility and Embryology Authority. Details of patient age and stage of disease at diagnosis, treatment given, current disease status, dates and treatment of relapse, semen analysis before and after treatment, marital status and number of children fathered prior to diagnosis of Hodgkin’s disease, use of cryopreserved semen, outcome of assisted reproduction and natural conceptions following treatment were obtained from case notes and the reproductive medicine data base. To compare semen quality between patients with multiple semen analyses a ‘best’ sample was selected by using a rank-sum procedure. Briefly, sperm concentration and motility were ranked independently and in ascending order, then the ranks of concentration and motility were summed for each sample. The highest rank-sum was used to select the ‘best’ semen specimen. The Kaplan–Meier method was used to estimate actuarial rates of semen utilisation, death without utilisation and destruction of semen without utilisation from the time of cryopreservation. The log-rank test was used to compare semen utilisation in men stratified according to marital status, number of children and age at diagnosis.

RESULTS

During the 12 year period 1978 to 1990, 122 men with a median age of 24 years (range 16 – 44 ) were eligible for inclusion in the study. As shown in Figure 1, the annual rate of referrals made for semen cryopreservation increased over this time. All patients received MVPP (mustine, vinblastine, prednisolone, procarbazine) or ChlVPP/EVA hybrid (chlorambucil, vinblastine, prednisolone, procarbazine, etoposide, vincristine, doxorubicin) chemotherapy either as adjuvant treatment following radiotherapy in early stage disease (MVPP) or for advanced stage disease (MVPP or ChlVPP/EVA hybrid) followed by radiotherapy to sites of initial bulk or residual masses. These regimens have equivalent gonadal...
Semen cryopreservation in men with Hodgkin’s disease
FH Blackhall et al

Figure 1 Men referred to Regional Fertility Centre between 1978 and 1990 for semen analysis and cryopreservation before treatment of Hodgkin’s disease.

Figure 2 Sperm motility vs concentration in 121 men with Hodgkin’s disease before start of treatment. Results for the ‘best’ samples analysed are shown (see Materials and Methods). Samples lying in the right upper quadrant, as defined by the horizontal line drawn at 50% motility and the vertical line drawn at 20 million per ml, are within the normal range for semen quality according to WHO criteria.

toxicity (Clark et al, 1995). In total, radiotherapy was administered to the pelvis following chemotherapy in three patients and to sites distant from the abdomen or pelvis in 82 patients.

Semen analysis before treatment

A median of four semen samples was analysed for each patient (range 1–7). For 121 out of 122 patients with complete data, the median sperm concentration was 50 × 10^6 per ml (range 0–306) and median sperm motility was 60 (range 0–90). Azoospermia (no sperm present in the ejaculate) and oligospermia (<20 × 10^6 per ml) were present in five and 25 patients respectively and severe oligospermia (≤10 × 10^6 per ml) was present in 13 out of 25 patients.

According to WHO criteria (WHO Laboratory Manual, 1992) 66% of patients in this series had a semen quality within the normal range (sperm concentration > 20 × 10^6 per ml and >50% motile sperm) (Figure 2). Semen was cryopreserved for 115 out of 122 patients (Figure 1). Reasons for not cryopreserving semen were azoospermia (n=5) and immotile sperm (n=2).

Semen analysis after treatment

Of 115 patients who cryopreserved semen, 97 patients were alive and disease free, one patient was alive with disease, 16 patients had died and there was incomplete data for one patient when this analysis was performed. After treatment, 74 patients requested semen analysis at least once (median=2, range 1–7) and at varying times following treatment depending on personal circumstances. At the first analysis, a median interval of 2.9 years (range 0.1–12.3) after completion of chemotherapy, the majority were azoospermic (68 out of 74) and four patients were oligospermic (1 × 10^6 per ml). Normal spermatogenesis was present in two patients (sperm concentrations of 25 million per ml and 50 million per ml), 79 and 54 months after treatment. Both patients had received only three of a planned eight cycles of MVPP. At subsequent analyses, recovery of spermatogenesis was detected in seven previously azoospermic patients although all remained severely oligospermic (sperm concentration <10 × 10^6 per ml). Overall, a degree of recovery of spermatogenesis occurred in 13 out of 74 patients at a median interval of 5.1 years (range 3.3–13.1) after treatment. To our knowledge, four patients in whom spermatogenesis recovered have fathered children naturally.

Assisted reproduction using cryopreserved semen

Data regarding utilisation was complete for 113 out of 115 patients who stored semen. The actuarial rate of utilisation 10 years from storage is 27%, the rate of destruction of semen without utilisation and before death of the patient is 19% and the rate of death without utilisation is 13% (Figure 3). Cryopreserved samples from 29 patients have been destroyed due to death (n=15), recovery of spermatogenesis (n=4) or at patient request with no reason specified (n=10). Patients who remain alive who have neither used nor destroyed cryopreserved semen have been followed for a median of 10.1 years. At the time of analysis, cryopreserved semen had been utilised for assisted reproduction by 33 couples. Grouping of patients according to whether or not they already had children or marital status at diagnosis revealed no group of patients who were significantly more or less likely to attempt assisted reproduction using cryopreserved semen (data not shown). Similarly, analysis by age at diagnosis also showed no significant difference in utilisation after 10 years (Figure 4) although numbers in each group were small.

During the course of this study a number of methods of assisted reproduction were used as treatments evolved and new techniques were introduced. At the start of the study in 1978, the only option was simple vaginal insemination or artificial insemination with husband’s sperm (AIH). In vitro fertilisation (IVF) was offered from 1984 onwards, and intracytoplasmic sperm injection (ICSI) from 1995 (Van Steirteghem et al, 1993). AIH was superceded by direct insemination into the uterine cavity (IUI) in 1995 (Horne et al, 1998). Of 33 couples receiving assisted reproduction, AIH was used by 28, IUI by two, and IVF or ICSI by three. Seven couples who originally received AIH went on to have IVF or ICSI as these techniques became available. In nine out of 33 couples, 10 pregnancies occurred of which eight resulted from AIH and two from IVF. One pregnancy (AIH) was terminated due to foetal malformation (hydrocephalus and cervical hygroma; normal female karyotype) but the remaining nine pregnancies resulted in the birth of 8 healthy singletons and one triplet of males to give a live birth rate of 27%. The triplet of males was the result of implantation of frozen thawed embryos from a second attempt at IVF using cryopreserved semen and ICSI, a particularly unusual case that has already been reported elsewhere (Horne et al, 2001). In 23 couples
assisted reproduction was not successful (see Table 1 for summary of reproductive outcomes).

**DISCUSSION**

The use of combination chemotherapy regimens has dramatically improved the prognosis for patients with Hodgkin’s disease. However, gonadal toxicity is common and for a number of years patients have been routinely counselled regarding this important late effect of treatment and offered semen cryopreservation. This policy initially met with the concern that sperm quality was adversely affected by Hodgkin’s disease itself and semen was therefore unlikely to be of use for cryopreservation and subsequent assisted reproduction (Whitehead et al, 1982). Several investigators have demonstrated relatively poor semen quality in patients with Hodgkin’s disease compared to healthy controls (Redman et al, 1987; Shekarriz et al, 1995), and patients with non-Hodgkin’s lymphomas (Botchan et al, 1997; Lass et al, 1998) although, consistent with the current study, a significant proportion of men with Hodgkin’s disease are found to have semen quality within the normal range at diagnosis.

There have been dramatic advances in reproductive medicine since the first reports of successful artificial insemination using cryopreserved semen from patients with Hodgkin’s disease (Scammell et al, 1985). The increasing availability of techniques such as ICSI means that semen containing even very low numbers of sperm should, nevertheless be cryopreserved (Lass et al, 1999). Furthermore, although in this series one pregnancy was terminated for foetal malformation there is no known increased risk of this complication in pregnancies resulting from the use of cryopreserved semen stored by patients with Hodgkin’s disease or other malignancies (Lansac et al, 1997).

This study confirms the high rates of sterility previously reported for MVPP and CHVPP/EVA hybrid chemotherapy (Whitehead et al, 1982; Clark et al, 1995) and highlights the increasing use of semen cryopreservation over time which probably reflects both a greater awareness of the importance of fertility issues for patients with a good prognosis and the availability of appropriate facilities. Although there are anecdotal reports of successful pregnancies following the use of cryopreserved semen in men with Hodgkin’s disease (Scammell et al, 1985; Redman et al, 1987; Milligan et al, 1989), to our knowledge, there are no published data describing the proportion of long term survivors of Hodgkin’s disease in the UK who attempt assisted reproduction and achieve success. Our retrospective data show that most patients have not used their cryopreserved semen (27% utilisation 10 years from storage, Figure 3) the reasons for which are unclear. Although factors such as disease status following treatment, age, marital status or number of children at diagnosis might be expected to have a bearing on reproductive decision making, our results imply other, as yet unidentified factors. In the UK these may include lack of immediate access to assisted reproduction treatment as many health authorities do not currently provide NHS funding. The Regional IVF and Donor Insemination treatment centre at St Mary’s Hospital in Manchester, for example, does provide NHS treatment but has a 3 – 4 year waiting list, does not treat couples who already have children living with them and has treated male factor infertility since only 1994. Workers from Australia (Audrins et al, 1999) have reported an even lower utilisation rate (7%) but in this study the mean follow-up time was only 3 years, a factor that may be important in evaluating this end point.

In the retrospective cohort reported here, approximately one-quarter have utilised cryopreserved semen following treatment for Hodgkin’s disease and of these, approximately one-quarter have

---

**Table 1** Reproductive outcome of 33 couples who have utilised cryopreserved semen

| Method of assisted reproduction | Number of patients | Number of pregnancies | Number of live births |
|--------------------------------|--------------------|-----------------------|-----------------------|
| Artificial insemination (AIH) or intrauterine insemination (IUI) | 30 | 8 (in 7 women)† | 7 |
| In vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) | 10 | 2 | 4 (1 set of triplets from frozen embryos obtained by IVF using ICSI) |

†One woman had a termination of pregnancy for foetal abnormality followed by a healthy livebirth.
still too young to start a family or have they opted never to have children? Is assisted reproduction acceptable to patients? Do they have access to all the reproductive technology currently available? And finally, are there fears regarding safety such as risk of disease transmission?

In addition to employing less toxic chemotherapy regimens wherever possible (Kulkarni et al, 1997) other strategies to overcome the impact of chemotherapy on reproductive function include the use of donor sperm for artificial insemination or IVF of the partner’s eggs, hormonal manipulations to enhance recovery of spermatogenesis (Meistrich, 1998) and cryopreservation with subsequent autotransplantation of testicular germ cells (Brook et al, 2001). There is no doubt, however, that men about to embark on a programme of sterilising chemotherapy should be offered semen cryopreservation as routine in the knowledge that the live birth rate following utilisation is at least 25%, a figure that is set to rise as a consequence of steady advances in reproductive medicine.

REFERENCES

Audrins P, Holden CA, McLachlan RJ, Kovacs GT (1999) Semen storage for special purposes at Monash IVF from 1977 to 1997. Fertil Steril 72: 179 – 191.

Botchan A, Hauser R, Gamzu R, Yogev L, Lessing JB, Paz G, Yavetz H (1997) Sperm quality in Hodgkin’s disease versus non-Hodgkin’s lymphoma. Hum Reprod 12: 73 – 76.

Brook PF, Radford JA, Shalet SM, Joyce AD, Gosden RG (2001) Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation. Fertil Steril 75: 269 – 274.

Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM (1995) Gonadal function following chemotherapy for Hodgkin’s disease: A comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 13: 134 – 139.

De Vita V, Canellos GP, Moxley GH (1972) A decade of combination chemotherapy in generalised Hodgkin’s disease. Cancer 30: 1495 – 1504.

Horne G, Critchlow JD, Newman MC, Falconer D, Pease EH, Lieberman BA (1998) A retrospective review of 3 years intrauterine insemination using cryopreserved donor sperm and cycle monitoring by urinary or serum LH measurements. Hum Reprod 11: 1420 – 1424.

Horne G, Atkinson A, Brison DR, Radford JA, Yin JA, Edi-Osagie EC, Pease EH, Lieberman BA (2001) Achieving pregnancy against the odds: successful implantation of frozen thawed embryos generated by ICSI using spermatooza banked prior to chemo/radiotherapy for Hodgkin’s disease and acute leukaemia. Hum Reprod 16: 107 – 109.

Human Fertilisation and Embryology Authority (1999) Annual Report.

Kulkarni SS, Sastry P, Saikia TK, Parikh PM, Gopal R, Advani SH (1997) Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 20: 354 – 357.

Lansac J, Thepot F, Mayaux MJ, Czyglick F, Wack T, Selva J, Jalbert P (1997) Pregnancy outcome after artificial insemination or IVF with frozen semen donor: a collaborative study of the French CECCOS Federation on 21,597 pregnancies. Eur J Obstet Gynecol Reprod Biol 74: 223 – 238.

Lass A, Akagbosu F, Abusheika N, Hassounah M, Blayney M, Avery S, Brin- den P (1998) A programme of semen cryopreservation for patients with malignant disease in a tertiary infertility centre: lessons from 8 years’ experience. Hum Reprod 13: 3256 – 3261.

Lass A, Abusheika N, Akagbosu F, Brinnsden P (1999) Cancer patients should be offered semen cryopreservation (letter). Br Med J 318: 1556.

Meistrich ML (1998) Hormonal stimulation of the recovery of spermatogenesis following chemo- or radiotherapy. Acta Pontologica Microbiologica et Immunologica, Scandinavica 106: 37 – 46.

Milligan DW, Hughes R, Lindsay KS (1989) Semen cryopreservation in men undergoing cancer chemotherapy – a UK survey. Br J Cancer 60: 966 – 967.

Redman JR, Bajorunas DR, Goldstein MC, Evenson DP, Gralla RJ, Lacher MJ, Koziner B, Lee BJ, Straus DJ, Clarkson BD (1987) Semen cryopreservation and artificial insemination for Hodgkin’s disease. J Clin Oncol 5: 233 – 238.

Scammell GE, Stedronska J, Edmonds DK, White N, Hendry WF, Jeffcoate SL (1985) Cryopreservation of semen in men with testicular tumour or Hodgkin’s disease: results of artificial insemination of their partners. Lancet 2: 31 – 32.

Shekarriz M, Tolentino MV, Ayrmaz I, Lee J, Thomas AJ, Agarwal A (1995) Cryopreservation and semen quality in patients with Hodgkin’s disease. Cancer 75: 2732 – 2736.

Van Steirteghem AC, Liu J, Joris H, Nagy Z, Jansenswillen C, Tournaye H, Derde MP, Van Assche E, Devroey P (1993) Higher success rate by intracytoplasmic sperm injection than by subzonal insemination. Report of a second series of 300 consecutive treatment cycles. Hum Reprod 8: 1055 – 1060.

Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG (1982) The effects of Hodgkin’s disease and combination chemotherapy on gonadal function in the adult male. Cancer 49: 418 – 422.

WHO Laboratory Manual (1992) WHO Laboratory Manual for the examination of human semen and semen-cervical mucus interaction, 3rd edn, Cambridge: The Press Syndicate of the University of Cambridge.